Last reviewed · How we verify
NCT06717100
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
Phase 1 trial testing Nintedanib 150 MG [Ofev] in Drug Interactions in 24 participants. Completed in 17 March 2025.
17 February 2025
Quick facts
| Lead sponsor | PureTech |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 17 December 2024 |
| Primary completion | 17 February 2025 |
| Estimated completion | 17 March 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Nintedanib 150 MG [Ofev] — full drug profile →
Conditions studied
- Drug Interactions — all drugs for Drug Interactions →
Sponsor
PureTech — full company profile →
Who can join
Adults 18 to 65, any sex, with Drug Interactions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06717100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nintedanib 150 MG [Ofev]
Trials testing the same drug.
- NCT05635071 — Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions · Phase 2, PHASE3 · unknown
Other recruiting trials for Drug Interactions
Currently open trials in the same condition.
- NCT06865885 — LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering · Phase 4 · recruiting
- NCT06757140 — Opioid Drug Interaction Study · Phase 1, PHASE2 · recruiting
- NCT06401863 — Shared Decision for Drug Interactions in Oral Anticoagulation · NA · recruiting
- NCT06159699 — Telecommunication Technology-based Online Survey · recruiting
Other PureTech trials
Trials by the same sponsor.
- NCT05321420 — LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · active not recruiting
- NCT05129865 — LYT-300 in Healthy Volunteers · Phase 1, PHASE2 · completed
- NCT07456800 — PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects · Phase 1 · completed
- NCT04666688 — LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid · Phase 1, PHASE2 · completed
- NCT04652518 — LYT-100 in Post-acute COVID-19 Respiratory Disease · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06717100 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PureTech
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06717100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing